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The pathogenesis of pulmonary infection and the immune response following intranasal inoculation of mice with two
equine herpesvirus type 1 (EHV-1) deletion mutants have been assessed. The mutants, ED71 and ED75, have deletions in
genes 71 (EUS4) and 75 (10K), respectively. Deletions were replaced by the Escherichia coli lacZ gene driven by the simian
virus 40 (SV40) early promoter. It has previously been shown that the protein products of genes 71 and 75 are dispensable
in vitro but that removal of gene 71 results in a defect in virus maturation and capsid envelopment which impairs the ability
of mutant virus to spread via release and readsorption. This study demonstrated that the 192-kDa gene 71 product is
required for full expression of virulence in mice, whereas the putative 10-kDa product of gene 75 has minimal effect. Both
mutants exhibited the same tissue and cytotropism as wild-type EHV-1 and induced both humoral and cell-mediated immune
responses indistinguishable from those induced by the parental strain. Irrespective of the reduced pathogenicity of the
gene 71 mutant, infected mice were protected against a challenge with wild-type EHV-1. These findings highlight the potential
of ED71 as a vaccine candidate. q 1997 Academic Press
INTRODUCTION 1995); and genes 1, 2, 67, 71, and 75 in EHV-1 (Audonnet
et al., 1992; Breeden et al., 1992; Colle et al., 1992; Telford
Equine herpesvirus type 1 (EHV-1) is a prevalent
et al., 1992). Counterparts of EHV-1 genes 71 (also desig-
equine pathogen which belongs to the subfamily Alpha-
nated EUS4) and 75 (also designated 10K) are alsoherpesvirinae (Roizman, 1992). Infection results espe-
thought to exist in EHV-4 (Cullinane et al., 1988; Nageshacially in respiratory disease, although abortion and neu-
et al., 1993). Of the five unique EHV-1 genes three, genesrological disease may also present (Campbell and Stud-
1, 67, and 75, were initially thought to have neither posi-dert, 1983; Allen and Bryans, 1986; Bryans and Allen,
tional nor sequence counterparts in other herpesviruses1989). The genome sequence and gene arrangement of
(Telford et al., 1992). However, positional counterparts ofa neuropathogenic isolate, Ab4, herein designated
genes 1 and 75 have since been found in other Alphaher-wtAb4p, have been determined by Telford et al. (1992).
pesvirinae. EHV-1 gene 1 has a counterpart in pseudora-The genome comprises two unique components, UL
bies virus (PRV) (Baumeister et al., 1995), and positional(112870 bp) and US (11861 bp), each bounded by inverted
homologs of EHV-1 gene 75 have been identified in HSV-repeat sequences TRL/IRL (32 bp) and IRS/TRS (12714 bp),
1 (Georgopoulou et al., 1993), and feline herpesvirus typerespectively. The short genome component exhibits the
1 (FHV-1) (Willemse et al., 1995). No definite functionsgreatest degree of sequence diversity among the Alpha-
have yet been assigned to any of the unique genes de-herpesvirinae described to date (Davison and Wilkie,
scribed above; however, their virus species-specificity1983), with a number of unique open reading frames
suggests that they might encode factors which confer a(ORFs) having been identified only in particular members
growth advantage in their respective natural hosts byof the subfamily. Exclusive short genome component
perhaps potentiating spread to a specific organ or cellORFs found among the Alphaherpesvirinae include: US5,
type within that host. Alternatively, they might serve in theUS11, and US12 in herpes simplex virus type 1 (HSV-1)
disabling of a particular specific or nonspecific antiviral(McGeoch et al., 1985) and herpes simplex virus type 2
response in the host. Thus an understanding of the func-(HSV-2) (McGeoch et al., 1987); US8.5 in HSV-1 (Georgo-
tions of these unique genes is likely to be important ifpoulou et al., 1993); ORF 1 in bovine herpesvirus type 1
we are to further our knowledge of the molecular mecha-(BHV-1) (Leung-Tack et al., 1994); sORF 1, 2, 3, and 4 in
nisms underlying herpesvirus pathogenesis.Marek’s disease virus (MDV) (Brunovskis and Velicer,
We present a phenotypic analysis in a well-defined
murine model for EHV-1 infection (Awan et al., 1990,1 To whom correspondence and reprint requests should be ad-
dressed. Fax: /44 1223 332998. E-mail: hjf10@cam.ac.uk. 1991; Azmi and Field, 1993a,b; Slater et al., 1993; Tewari
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et al., 1994; Osterrieder et al., 1995) of two isogenic b-
galactosidase-positive (b-gal/) deletion mutants of EHV-
1, designated ED71 and ED75, with the Escherichia coli
lacZ gene under control of the simian virus 40 (SV40)
early enhancer/promoter replacing deletions in genes 71
and 75, respectively. Using these mutants it has been
shown previously that neither gene 71 nor gene 75 is
required for EHV-1 replication in tissue culture (Sun and
Brown, 1994). However, the gene 71 product has been
recently shown to play a part in virus adsorption, penetra-
tion, and egress from tissue culture cells (Sun et al.,
1996). The mutants, ED71 and ED75, form part of a series
of EHV-1 lacZ recombinants which have been con-
structed to facilitate the study of the functions of a num-
ber of genes unique to EHV-1 (Sun and Brown, 1994; Sun
et al., 1995). This paper represents the first account of
the in vivo properties of two of these mutants.
MATERIALS AND METHODS
Cells and viruses
All viruses used were derived from EHV-1 strain Ab4.
Two wild-type viruses, termed wtAb4 and wtAb4p, were
FIG. 1. (a) Cartoon of EHV-1 genome showing the US , IRS, and TRSused where wtAb4 is a British field isolate, and wtAb4p
genome segments and location of restriction fragments D1 and D2. (b)is a plaque-purified isolate of wtAb4. Two recombinant
Detail of D1 and D2 showing positions of ORFs (arrows) and points of
viruses, ED71 and ED75, constructed from wtAb4p (pas- insertion of lacZ cassettes in ORFs 71 and 75 in ED71 and ED75,
saged 13 times in equine cells) and expressing the E. respectively. ORFs are numbered according to the nomenclature of
Telford et al. (1992), with HSV equivalent ORFs shown in italics. Restric-coli lacZ gene were also used in this study. Prior to
tion enzyme sites are indicated by B, BamHI; E, EcoRI. Not drawn tocommencing this work, all viruses were passaged twice
scale.in rabbit kidney fibroblast (RK-13) cells (Christofinis and
Beale, 1968) grown at 377 in Eagle’s minimal essential
medium (EMEM) containing 1% fetal calf serum (FCS).
signs. Sixteen mice from each of the experimental groupsThe construction of mutants ED71 and ED75 has been
were used for virus isolation, with 4 mice being killeddescribed in detail by Sun and Brown (1994). ED71 has
from each group on Days 1, 3, 5, and 7 postinfectiona 1811-bp deletion in gene 71 replaced by a cassette
(p.i.). A further 4 mice were used for the collection ofcontaining the lacZ gene under the control of the SV40
serum samples from the tail vein on Days 0, 3, 7, 14,early enhancer/promoter (Fig. 1b). ED75 contains the
21, 28, 42, and 56 p.i. for enzyme-linked immunosorbentsame cassette replacing a 189 bp deletion in gene 75
assay (ELISA). After collection of the final serum samples,(Fig. 1b). Thus 76 and 48%, respectively, of the coding
the same animals were used for determination of cell-sequences of genes 71 and 75 have been deleted. The
mediated immune responses by delayed-type hypersen-correct points of insertion of the lacZ cassette in ED71
sitivity (DTH) skin tests. The remaining 8 mice from eachand ED75 have been previously confirmed by restriction
group were used for histology, X-gal reaction, and elec-enzyme digestion (Sun and Brown, 1994).
tron microscopy. All experiments included negative con-
trols comprising uninfected mice as well as mice havingExperimental procedures
received RK-13 cell lysates. Challenge experiments were
performed on three groups of 20 mice immunized by i.n.All in vivo experiments were performed using female
4-week-old BALB/c mice obtained from Bantin and King- inoculation with 1 1 107 PFU/mouse of wtAb4p, ED71,
or ED75. Control mice were immunized with RK-13 cellman (Grimston, Aldbrough, Hull, UK). Infections were es-
tablished as described previously (Awan et al., 1990) by lysate. Inoculum titers were reconfirmed as above and,
on Days 3 and 5 p.i., virus isolations were made from 2i.n. infection with 1 1 107 PFU/mouse of the parental
virus wtAb4p, ED71, or ED75. Inoculum titers were recon- mice in each group to verify that infections had been
established successfully (not shown). After 60 days, allfirmed by back titration of residual inoculum. In order to
study primary infections in the mouse, three groups of surviving mice were given an i.n. challenge with 1 1 108
PFU (LD50 1 20) of wtAb4. Serum antibody titers were34 mice were infected i.n. with virus. Six mice from each
group were caged separately and used to record clinical measured in 4 mice on Days 04, 0, 3, 7, 14, 21, and 28
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postchallenge infection (p.c.i.) by indirect ELISA. On Day
28 p.c.i. DTH skin tests were performed in the same 4
mice from each group. Virus clearance rates from nasal
turbinates and lung were determined by plaque-assay of
tissue homogenates prepared from 3 mice on Days 1, 3,
and 5 p.c.i. Three additional groups of 10 mice which
had been immunized with wtAb4p, ED75, or ED71 and
subsequently challenged as above were housed sepa-
rately and used to record clinical signs.
The extent to which mutant viruses were attenuated
was evaluated by intracerebral (i.c.) injection. Increasing
doses of virus suspended in 20 ml of EMEM were injected
at a depth of approximately 2 mm into the left cerebral
hemisphere of groups of six 4-week-old anesthetized
BALB/c mice. Survival rates were then recorded over a
14-day period.
Rescue of ED71 and ED75
Two rescuants of ED71 and ED75, termed RED71 and
RED75, respectively, were constructed. The 10.5-kb FIG. 2. Weight changes in 4-week-old female BALB/c mice following
i.n. infection with 1 1 107 PFU of wtAb4p (m), ED75 (h), or ED71 (s).BamHI ‘‘D’’ fragment of EHV-1 containing most of the
Data points represent mean percentages { SD; n  6.unique short genome component was cloned into
pBR322 to give plasmid pBRD. Following double diges-
tion of pBRD with BamHI and EcoRI, the 5.8-kb D1 and
RESULTS4.7-kb D2 subfragments (Fig. 1b) were purified from elec-
trophoresis gels by the glass powder method (Qiagen, Pathogenesis following i.n. infection in BALB/c mice
UK). The D1 and D2 fragments were then cotransfected
The severity of clinical signs following i.n. infection atalong with ED71 and ED75 DNA into RK-13 cells, respec-
1 1 107 PFU/mouse occurred in the order: wtAb4p tively, using the method of Stow et al. (1976). Rescued
ED75  ED71. On Day 1 p.i. all mice were hunched andviruses were selected by blue/white screening in the
had ruffled fur. At 3 days p.i. wtAb4p- and ED75-infectedpresence of 0.05 mg/ml X-gal (5-bromo-4-chloro-3-indoyl
mice continued to show these signs and their breathingb-D-galactopyranoside) and were subsequently plaque-
was labored (dyspnoea) and abdominal as well as morepurified three times.
rapid (tachypnoea) than that of control mice. Substantial
weight loss was also evident in these groups, while
X-gal reaction ED71-infected mice showed no obvious clinical signs
and weights had started to return toward preinfection
Whole tissues to be reacted with X-gal were fixed in values (Fig. 2). At 5 days p.i., wtAb4p- and ED75-infected
4% paraformaldehyde on ice for 1 hr. After being washed mice showed average weight losses of around 47 and
in PBS, the tissues were placed in X-gal reaction solution 21% of preinfection values, respectively, whereas ED71-
(0.1% (w/v) Na desoxycholate, 0.1% (v/v) NP-40, 5 mM infected mice had attained their preinfection weights at
potassium ferricyanide, 5 mM potassium ferrocyanide, 2 this time (Fig. 2). wtAb4p-infected mice remained abnor-
mM MgCl2 , and 1 mg/ml X-gal) and incubated for 18 hr mal for up to 12 days p.i., and two deaths occurred at 8
at 337. After being washed in PBS, they were fixed in 10% days p.i. Both fatalities occurred in animals whose
Formalin overnight prior to embedding and sectioning. weights had dropped below 7 g. No deaths were re-
Sections were counterstained with hematoxylin and eo- corded in either the ED75- or ED71-infected groups.
sin and mounted with DPX (BDH, Poole, UK). The ability of mutants ED71 and ED75 to replicate in
the respiratory tissues of the BALB/c mouse was com-
pared by assay for infectious virus in nasal turbinate andOther methods
lung homogenates. Replication of mutant ED75 in the
nasal turbinates mirrored that of the parent virus, andMethods for the titration of viruses in tissue samples,
preparation of tissues for histological and electron micro- no significant differences were observed between the
groups at the time points examined (Fig. 3a). The lungscopic examination, ELISA, and DTH skin tests were as
described previously (Awan et al., 1990; Azmi and Field, virus content was also similar in the ED75- and wtAb4p-
infected groups; however, a significant reduction in virus1993a).
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FIG. 3. Geometric mean virus content on Days 1, 3, 5, and 7 p.i. in nasal turbinates (a) and lung (b) of 4-week-old female BALB/c mice following
i.n. infection with 1 1 107 PFU of wtAb4p ( ), ED75 ( ), or ED71 (h). All plaque assays of tissue homogenates were performed in triplicate.
titer was recorded (Fig. 3b) at 7 days p.i. in ED75-infected In agreement with the cytotropism of wtAb4 in lung, as
previously determined by immunohistochemical staininganimals (Student’s t test P  0.05). In contrast, ED71
replicated poorly in respiratory tissues, as evidenced by and in situ hybridization (Awan et al., 1990; Baxi et al.,
1996), the bronchial and bronchiolar epithelia were foundrapid virus clearance from both nasal turbinates and lung
(Figs. 3a and 3b), while the ED71 rescuant, RED71, repli- to be infected with ED75 and ED71, as evidenced by
deposits of blue reaction product within the ciliated epi-cated with wild-type kinetics in both nasal turbinates and
lung (not shown). thelium following reaction of whole lung with the chromo-
FIG. 4. Sections through the lung of 4-week-old female BALB/c mice infected with 1 1 107 PFU of ED75 (A) or ED71 (B). The sections were
counterstained with H / E following whole tissue X-gal reaction at 5 and 2 days p.i., respectively. In both (A) and (B) the bronchiole B is lined with
blueb-gal/ epithelial cells (arrow) indicating the presence of b-gal/ ED75 and ED71, respectively. Epithelial cells are seen detaching and desquamat-
ing into the lumen (L).
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TABLE 1 tion (hunching, ruffled fur, and dyspnoea); however, pro-
tection against lethal dose challenge infection was alsoPercentage Survival Rates in 4-Week-Old BALB/c Mice at 14 Days
observed in these animals. A reduction in virus titersp.i. Following i.c. Injection with Increasing Titers of wtAb4p, ED75,
or ED71 was evident in all experimental groups in both nasal
turbinates and lung relative to that of uninfected control
Virus titers (PFU/mouse) mice that had been inoculated previously with RK-13 cell
lysate (Figs. 6a and 6b). The greatest reductions in virusVirus 1 1 105 5 1 105 1 1 106 1 1 107 1 1 108
titers were seen in mice immunized with wtAb4p and
wtAb4p 100a 50 33 0 0 ED75, although increased virus clearance from both na-
ED75 100 100 67 33 0 sal turbinates and lung was also observed in mice immu-
ED71 100 100 100 100 100 nized with ED71 (Figs. 6a and 6b). No detectable differ-
ences were apparent in the secondary IgM, IgG, or cell-a Percentage of mice surviving infection (n  6).
mediated immune responses induced against wtAb4 in
the wtAb4p-, ED75-, or ED71-immunized groups (Fig. 5b
and Table 3).genic substrate X-gal (Figs. 4A and 4B). No evidence of
b-galactosidase activity was found in the lungs of mice
infected with either the lacZ-negative parent virus or RK- DISCUSSION
13 cell lysate. In general, lung pathology following ED71
The salient points of our research were (i) deletion ofinfection was milder than that observed in wtAb4p- or
the gene 71 ORF (EUS4) resulted in a virus exhibiting aED75-infected mice. Consolidation of the pulmonary tis-
greatly attenuated phenotype following i.n. infection insue, a prominent feature of the lung pathology observed
BALB/c mice and in agreement with the in vitro findingsin wtAb4p- and ED75-infected animals, was not observed
of Sun et al. (1996) there was an obvious deficit of enve-in ED71-infected mice.
loped virions in infected epithelial cells, with little or noIn order to reaffirm the apparent attenuated pheno-
reduplication and invagination of the nuclear membrane;types of ED71 and ED75, the survival rates in mice were
(ii) deletion of gene 71 had no apparent effect upon stimu-compared following i.c. infection with increasing titers of
lation of antibody or cell-mediated immune responses;wild-type and mutant viruses. Groups of six mice were
(iii) a gene 75 deletion mutant was moderately attenuatedinfected with 1 1 105, 5 1 105, 1 1 106, 1 1 107, or 1
in this infection model; (iv) the wild-type phenotype could1 108 PFU/mouse and monitored over a 14-day period.
be restored by constructing rescuant viruses; and (v) bothNumbers of mice surviving after 14 days are given in
ED71 and ED75 conferred protection against lethal doseTable 1. Survival rates of 100% were recorded for all
wild-type challenge.groups when inoculated at a titer of 1 1 105 PFU/mouse.
The gene 71 product is thought to be a high-abun-At 5 1 105 PFU this decreased to 50% in mice infected
dance highly glycosylated membrane glycoprotein (Sunwith wild-type virus and decreased further to 33% at 1 1
et al., 1994), and it is perhaps not unexpected that its106 PFU. At a dose greater than or equal to 1 1 107 PFU
absence from the ED71 envelope culminates in havingno mice survived a wild-type infection. In the case of
such a marked effect upon EHV-1 pathogenicity. A promi-ED75, a dose of 1 1 106 PFU was needed to cause
nent feature of the gene 71 protein is a region of re-lethality, with a survival rate of 67%. At 1 1 107 PFU this
peating serine and threonine residues believed to bedecreased to 33%. All mice inoculated with the mutant
sites of O-linked glycosylation. This glycosylated proteinED71 survived the infection, including those receiving
domain has been proposed to form a semiflexible rod ofthe maximum dose of 1 1 108 PFU.
some 70 nm in length situated on the outer surface of
the virion envelope (McGeoch et al., 1993). The absenceImmune responses to wtAb4p, ED75, and ED71
of such a topographic feature on the virion envelope
surface might well be expected to have a deleteriousExamination of the primary antibody (IgG and IgM)
and cell-mediated immune responses elicited in mice effect upon virus replication. The nonappearance of gene
71 in other Alphaherpesvirinae but its requirement forinfected with either of the recombinant viruses or the
parental strain revealed no detectable differences in the efficient virus adsorption, penetration, egress (Sun et al.,
1996), and full expression of EHV-1 virulence in vivomagnitude and duration of antibody or cell-mediated im-
mune responses (Fig. 5a and Table 2). Following i.n. would suggest that the biological functions provided by
the gene 71 product are supplied by other membranechallenge infection with wtAb4, wtAb4p- and ED75-im-
munized mice showed only moderate weight losses p.c.i. glycoproteins in other Alphaherpesvirinae.
HSV-1 US5, the positional homolog of gene 71, hasof around 5% of preinfection weights, and survival rates
in a group size of 10 mice were 100% in both cases. No been demonstrated to be nonessential both in vitro and
in the mouse (Balan et al., 1994). However, the US5 pro-clinical signs of infection were evident in either group.
ED71-protected mice showed mild signs of EHV-1 infec- tein displays no homology to the gene 71 product (Fast
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FIG. 5. (a) Primary serum antibody titers of IgM (dashed lines) and IgG (solid lines) following i.n. infection with 1 1 107 PFU/mouse of wtAb4p
(m), ED75 (h), or ED71 (s). (b) Secondary serum antibody titers of IgM (dashed lines) and IgG (solid lines) in mice erstwhile inoculated with 1 1
107 PFU of wtAb4p (m), ED75 (h), and ED71 (s) and subsequently challenged at 60 days p.i. with 1 1 108 PFU/mouse of wtAb4. Data are geometric
means of duplicate serum samples collected from four mice { SD. Titers were determined by an indirect ELISA as described previously (Azmi and
Field, 1993a).
A score 24) (Telford et al., 1992) and encodes a much Colle et al. (1996) have recently determined that the
Kentucky A (KyA) strain of EHV-1 lacking ORFs 1 and 2smaller 92-amino-acid protein (McGeoch et al., 1985).
Much of the region deleted in gene 71 in the mutant and those encoding EHV-1 homologs of gI, gE, and a
potential 10-kDa protein (gene 75), as well as havingED71 comprises a series of tandem sequence reitera-
tions. As suggested previously by Telford et al. (1992), substantial deletions in ORF 17 and EUS4 (gene 71), is
greatly attenuated in the mouse model. Moreover, KyAindirect evidence that these tandem reiterations are im-
portant determinants of protein structure and function has also been shown to be attenuated in the horse (Mat-
sumura et al., 1996). It is not known which of the deletionscomes from the fact that both EHV-1 gene 24 and its HSV-
1 counterpart, UL36, contain tandem repeat elements in in KyA are directly responsible for the decrease in viru-
lence; however, from our own observations it is clear thatthe same location of their coding sequences. Possibly,
expansion or contraction of the region comprising the the deletion in gene 71 (EUS4) is a contributory factor.
Deletion of gene 75 (10K) had little effect upon virustandem reiterations of gene 71 has an effect upon protein
folding and protein topography. In turn, this might influ- replication and pathogenicity in mice. Although we did
observe a significant reduction in weight loss in miceence the affinity of the gene 71 product for a putative
cellular receptor affecting virus infectivity and hence the infected with ED75 (Fig. 2) compared to mice receiving
wild-type infections, this did not reflect the degree ofpathogenicity of the virus.
lung pathology or the extent of virus replication observed
in ED75-infected mice, which suggested only a moder-
TABLE 2 ately attenuated phenotype. The EHV-1 gene 74 (gE) and
DTH Responses to Wild-Type Virus Following Primary Infection gene 75 transcripts are thought to be 3* coterminal and
with wtAb4p, ED75, or ED71a encoded from a single polycistronic message (Elton et
al., 1991). We have not established what effect cloning
Primary Time p.i. (hr)
the lacZ gene into gene 75 coding sequences has uponvirus
expression of gene 74. It will be important to verify thatinfection 0 24 48
the slight reduction in virulence exhibited by ED75 is
wtAb4p 0 (0)b 23.8 (2.6) 20.4 (2.2) due to lack of gene 75 and not due to anomalous expres-
ED75 0 (0) 26.1 (1.9) 21.2 (2.1) sion of gE or gE/gI. HSV-1 and PRV gE0 mutants are
ED71 0 (0) 25.9 (2.4) 20.7 (2.1)
known to exhibit reduced virulence thought to be as a
result of impaired transneuronal spread (Kimman et al.,a Details in text.
b Mean ear thickness increase (mm 1 102 ({SD)). 1992; Dingwell et al., 1995). In passing, it is also worth
AID VY 8483 / 6a31$$$361 03-31-97 17:48:19 vira AP: Virology
26 MARSHALL ET AL.
FIG. 6. Reduction in target organ virus content in nasal turbinates (a) and lung (b) in mice immunized by i.n. infection with 1 1 107 PFU of wtAb4p
( ), ED75 ( ), ED71 (h), or RK-13 cell lysate ( ) and challenged at 60 days p.i. with 1 1 108 PFU/mouse of the non-plaque-purified isolate, wtAb4.
Data are expressed as geometric means of three mice { SD.
noting that, in the case of HSV-1, the considerable over- of mice with EHV-4, which does not replicate in the
mouse, has been shown previously to confer protectionlap between US8 (gE) and US8.5 coding sequences
means that many gE0 mutants will also be US8.5
0, a fact against subsequent EHV-1 challenge (Azmi and Field,
1993b). However, in this instance mice became sensi-not recognized before US8.5 was identified by Georgo-
poulou et al. (1993). tized, resulting in an increase in immunopathology, par-
ticularly in the lung (Azmi and Field, 1993b). These resultsThere were no observable differences in magnitude
and duration of primary and secondary humoral or cell- suggest that ED71 might merit further evaluation in the
natural host as a potential EHV-1 vaccine.mediated immune responses in mice infected with either
parental or recombinant viruses. The antibody responses
to all three viruses were very low; however, this has been ACKNOWLEDGMENTS
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